In Celexir’s organ-support lineup, Bronchogen is positioned for patients needing targeted pulmonary recovery—chronic respiratory conditions, post-COVID convalescence, or environmental/lifestyle lung stress. It’s designed to slot into integrative pulmonary care programs that pair breathing mechanics, sleep, and inflammation control with tissue-level support.
Mechanistically, Bronchogen is a peptide bioregulator directed at bronchial epithelial protein-synthesis pathways. By promoting tissue regeneration, stabilizing alveolar structures, and improving resilience against inflammation and oxidative damage, it aims to preserve gas-exchange architecture while the upstream drivers of injury are addressed.
From a clinical standpoint, deploy Bronchogen as an adjunct within a broader lung-health plan—airway hygiene, rehab, sleep/circadian alignment, and anti-inflammatory nutrition—while tracking objective markers (symptom burden, rescue-inhaler use, recovery time). Frame use as part of an evidence-informed program focused on function and resilience in at-risk or recovering patients.
Celexir delivery & specs: Lyophilized or liquid prefilled pen, >98% purity (HPLC-validated), 2–8 °C storage, full CoA/MSDS, and protocols typically using 10–20 injections per cycle—built to keep dosing consistent and workflow clean from warehouse to administration.